Targeting Glutamine Metabolism in Prostate Cancer
Frontiers in Bioscience-Elite · 2023
DOI: 10.31083/j.fbe1501002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Elite, 2023. Verfasst von Neil Bhowmick und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, …. Hauptthemen laut MEDLINE: Glutamine, Prostatic Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCI NIH HHS, Department of Defense.
Abstract (Originalsprache)
Glutamine is a conditionally essential amino acid important for cancer cell proliferation through intermediary metabolism leading to de novo synthesis of purine and pyrimidine nucleotides, hexosamine biosytnehsis, fatty acid synthesis through reductive carboxylation, maintenance of redox homeostasis, glutathione synthesis, production of non-essential amino acids, and mitochondrial oxidative phosphorylation. Prostate cancer has increasingly been characterized as a tumor type that is heavily dependent on glutamine for growth and survival. In this review, we highlight the preclinical evidence that supports a relationship between glutamine signaling and prostate cancer progression. We focus on the regulation of glutamine metabolism in prostate cancer through key pathways involving the androgen receptor pathway, MYC, and the PTEN/PI3K/mTOR pathway. We end with a discussion on considerations for translation of targeting glutamine metabolism as a therapeutic strategy to manage prostate cancer. Here, it is important to understand that the tumor microenvironment also plays a role in facilitating glutamine signaling and resultant prostate cancer growth. The druggability of prostate cancer glutamine metabolism is more readily achievable with our greater understanding of tumor metabolism and the advent of selective glutaminase inhibitors that have proven safe and tolerable in early-phase clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- Department of Surgery, Division of Cancer Biology and Therapeutics, Biomedical Sciences, and Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Förderung
- BLRD VA
- NCI NIH HHS
- Department of Defense
- National Cancer Institute
- US Department of Veterans Affairs
Zitieren
APA
Bhowmick, N., Posadas, E., Ellis, L., Freedland, S. J., Vizio, D. D., Freeman, M. R., Theodorescu, D., Figlin, R., & Gong, J. (2023). Targeting Glutamine Metabolism in Prostate Cancer. Frontiers in Bioscience-Elite. https://doi.org/10.31083/j.fbe1501002
Vancouver
Bhowmick N, Posadas E, Ellis L, Freedland SJ, Vizio DD, Freeman MR, et al. Targeting Glutamine Metabolism in Prostate Cancer. Frontiers in Bioscience-Elite. 2023. doi:10.31083/j.fbe1501002
BibTeX
@article{Bhowmick2023,
author = {Bhowmick, Neil and Posadas, Edwin and Ellis, Leigh and Freedland, Stephen J and Vizio, Dolores Di and Freeman, Michael R and Theodorescu, Dan and Figlin, Robert and Gong, Jun},
title = {Targeting Glutamine Metabolism in Prostate Cancer},
journal = {Frontiers in Bioscience-Elite},
year = {2023},
doi = {10.31083/j.fbe1501002}
}
EUVIMED